Tagged with Diabetes

Pharma Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy, and the limitations of Hungary’s regulatory framework. Zsolt, you took over the helm of Novo Nordisk Hungary in 2012, after…

Pharma After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses the challenges the company is facing as well as the initiatives in place to increase market access and affordability. Could…

Pharma The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s rich pipeline is set to boost growth in new areas over the next few years. We interviewed you during your…

Pharma With a large and growing population, and significant domestic health needs, Lilly Egypt general manager Ozkan Ozdogan sees many opportunities for various stakeholders to serve patients, and is focusing on improving healthcare practitioners’ ability to better train diabetes patients to manage their condition.    After 14 years with Lilly Turkey in…

Pharma Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently being implemented in the regulatory system will have on the industry moving forward.   Dr. Piliounis, to start off, you…

Pharma Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new products the company’s pipeline holds for the future. When we interviewed Takeda in 2009, you were ranked 20th in the…

Pharma Prof. Manuela Battaglia (MB) and  Prof. Lorenzo Piemonti (LP) discuss the positioning of the Diabetes Research Institute (DRI) within the San Raffaele Scientific Institute and the global diabetes care community, their respective specialty areas and DRI’s commitment to translational medicine. The Diabetes Research Institute (DRI) is part of the International…

Pharma Medical Union Pharmaceuticals (MUP) acquired Lilly’s Egyptian human insulin vial manufacturing facility in early 2015. Managing Director Ahmed Kelani discusses the national significance of this acquisition given Egypt’s high prevalence of diabetes, and how the transferred technology will support MUP’s ambition to become a leading pharmaceutical manufacturer in the region.…

Pharma Egypt is at the ‘golden stage’ for investment, claims Boehringer Ingelheim country head Mohamed El-Sahhar, who explains how the company is expanding their organization in Egypt ahead of an expansion into diabetes and oncology.  Egypt’s international image is still heavily influenced by the political instability of 2011 to 2013; what…

Pharma Novasep is the largest contract manufacturer for the pharmaceuticals and fine chemicals industries in France. Michel Spagnol, the company’s chairman and CEO, highlights recent reorganization and “back to basics” strategy based on organic growth improving the product mix and underscoring new investments. What is your perspective regarding the state of…

Pharma In Egypt’s diverse marketplace, Novo Nordisk is bringing care to patients across the country with a range of products ranging from affordable established insulin to their most recent generation of innovative products. At the same time, they are investing in localizing production of insulin in Egypt and encouraging best practices in diabetes…

diabetes